IN8bio, Inc.
INAB
$1.55
-$0.11-6.63%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.63% | -15.96% | -6.46% | -8.57% | -2.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.69% | -15.40% | -3.48% | 2.51% | 5.41% |
| Operating Income | 28.69% | 15.40% | 3.48% | -2.51% | -5.41% |
| Income Before Tax | 25.25% | 11.66% | -1.43% | -5.52% | -5.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.25% | 11.66% | -1.43% | -5.52% | -5.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.25% | 11.66% | -1.43% | -5.52% | -5.00% |
| EBIT | 28.69% | 15.40% | 3.48% | -2.51% | -5.41% |
| EBITDA | 31.04% | 16.50% | 3.71% | -1.87% | -3.68% |
| EPS Basic | 59.26% | 47.60% | 40.21% | 33.00% | 32.93% |
| Normalized Basic EPS | 61.99% | 50.07% | 43.16% | 35.78% | 33.64% |
| EPS Diluted | 59.26% | 47.60% | 40.21% | 33.00% | 32.93% |
| Normalized Diluted EPS | 61.99% | 50.07% | 43.16% | 35.78% | 33.64% |
| Average Basic Shares Outstanding | 111.85% | 84.81% | 79.87% | 57.60% | 57.39% |
| Average Diluted Shares Outstanding | 111.85% | 84.81% | 79.87% | 57.60% | 57.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |